{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:21:19Z","timestamp":1769826079741,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"This study was funded by Hexal AG, a Sandoz company."},{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s12325-023-02706-8","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T05:01:40Z","timestamp":1699678900000},"page":"315-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-2299","authenticated-orcid":false,"given":"Marc","family":"Schmalzing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Askari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"De Toro Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio Cesar","family":"Vazquez Perez-Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Foti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u0142awomir","family":"Jeka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boulos","family":"Haraoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Peichl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Oehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masiur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabricio","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohaib","family":"Hachaichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Both","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Brueckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Sheeran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"issue":"4","key":"2706_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40744-019-00172-9","volume":"6","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Liu M, Rebello S, et al. Comparative disease burden in patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis: data from two corrona registries. Rheumatol Ther. 2019;6(4):529\u201342.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"2706_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40744-021-00407-8","volume":"9","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Bhutani MK, Hass S, Yi E, Hur P, Kim N. Comparison of clinical manifestations in rheumatoid arthritis vs. spondyloarthritis: a systematic literature review. Rheumatol Ther. 2022;9(2):331\u201378.","journal-title":"Rheumatol Ther"},{"key":"2706_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102234","volume":"64","author":"CA Conran","year":"2022","unstructured":"Conran CA, Moreland LW. A review of biosimilars for rheumatoid arthritis. Curr Opin Pharmacol. 2022;64:102234.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"2706_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/ar592","volume":"4","author":"J Braun","year":"2002","unstructured":"Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res. 2002;4(5):307\u201321.","journal-title":"Arthritis Res"},{"issue":"1","key":"2706_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1080\/03009742.2021.1997436","volume":"51","author":"AM Kerola","year":"2023","unstructured":"Kerola AM, Rollefstad S, Kazemi A, et al. Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents. Scand J Rheumatol. 2023;51(1):42\u201350.","journal-title":"Scand J Rheumatol"},{"issue":"9227","key":"2706_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385\u201390.","journal-title":"Lancet"},{"issue":"2","key":"2706_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/art.20019","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(2):353\u201363.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2706_CR8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582\u201391.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2706_CR9","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136\u201346.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2706_CR10","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 2019;71(7):1112\u201324.","journal-title":"Arthritis Rheumatol"},{"key":"2706_CR11","doi-asserted-by":"publisher","first-page":"1759720X2096403","DOI":"10.1177\/1759720X20964031","volume":"12","author":"C Bruni","year":"2020","unstructured":"Bruni C, Gentileschi S, Pacini G, et al. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. Ther Adv Musculoskelet Dis. 2020;12:1759720X20964031.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"2706_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40744-021-00418-5","volume":"9","author":"E Feist","year":"2022","unstructured":"Feist E, Baraliakos X, Behrens F, et al. Effectiveness of etanercept in rheumatoid arthritis: real-world data from the German non-interventional study ADEQUATE with focus on treat-to-target and patient-reported outcomes. Rheumatol Ther. 2022;9(2):621\u201335.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"2706_CR13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/annrheumdis-2012-202715","volume":"72","author":"T D\u00f6rner","year":"2013","unstructured":"D\u00f6rner T, Strand V, Casta\u00f1eda-Hern\u00e1ndez G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2013;72(3):322\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2706_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.blre.2014.08.003","volume":"28","author":"BR Hirsch","year":"2014","unstructured":"Hirsch BR, Lyman GH. Biosimilars: a cure to the U.S. health care cost conundrum? Blood Rev. 2014;28(6):263\u20138.","journal-title":"Blood Rev"},{"key":"2706_CR15","unstructured":"Biosimilars in the EU: information guide for healthcare professionals 2019. https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 14 Jun 2022"},{"issue":"6","key":"2706_CR16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40259-017-0246-1","volume":"31","author":"ED Deeks","year":"2017","unstructured":"Deeks ED. GP2015: an etanercept biosimilar. BioDrugs. 2017;31(6):555\u20138.","journal-title":"BioDrugs"},{"key":"2706_CR17","unstructured":"Sandoz GmbH. Erelzi: EU summary of product characteristics. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/erelzi-epar-product-information_en.pdf. Accessed 14 Jun 2022."},{"key":"2706_CR18","doi-asserted-by":"crossref","unstructured":"Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2\u201310.","DOI":"10.1002\/pds.3891"},{"issue":"4","key":"2706_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"20","key":"2706_CR20","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"issue":"9","key":"2706_CR21","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/art.40516","volume":"70","author":"L Tweehuysen","year":"2018","unstructured":"Tweehuysen L, Huiskes VJB, van den Bemt BJF, et al. Open-label, non-mandatory transitioning from originator etanercept to biosimilar SB4: six-month results from a controlled cohort study. Arthritis Rheumatol. 2018;70(9):1408\u201318.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2706_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1136\/annrheumdis-2018-213474","volume":"78","author":"B Glintborg","year":"2019","unstructured":"Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78(2):192\u2013200.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2706_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3899\/jrheum.181398","volume":"47","author":"P Emery","year":"2020","unstructured":"Emery P, Vlahos B, Szczypa P, et al. Longterm drug survival of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol. 2020;47(4):493\u2013501.","journal-title":"J Rheumatol"},{"issue":"9","key":"2706_CR24","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1093\/rheumatology\/keab933","volume":"61","author":"D Di Giuseppe","year":"2021","unstructured":"Di Giuseppe D, Lindstrom U, Bower H, et al. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden. Rheumatology (Oxford). 2021;61(9):3596\u2013605.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2706_CR25","first-page":"1238","volume":"28","author":"LW Moreland","year":"2001","unstructured":"Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol. 2001;28(6):1238\u201344.","journal-title":"J Rheumatol"},{"issue":"6","key":"2706_CR26","first-page":"344","volume":"23","author":"F Atzeni","year":"2021","unstructured":"Atzeni F, Gerratana E, Bongiovanni S, et al. Efficacy and safety of biosimilar and originator etanercept in rheumatoid arthritis patients: real-life data. Isr Med Assoc J. 2021;23(6):344\u20139.","journal-title":"Isr Med Assoc J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02706-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02706-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02706-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T22:07:02Z","timestamp":1705615622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02706-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,11]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2706"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02706-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,11]]},"assertion":[{"value":"22 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marc Schmalzing: Compensation for consultancies: Chugai\/Roche, Hexal\/Sandoz, Gilead, AbbVie, Janssen-Cilag, Boehringer\/Ingelheim, onkowissen.de, EUSA-Pharma, Novartis, AstraZeneca, Amgen, medac, Lilly, Galapagos, UCB; Speaker\u2019s fees: Novartis, AbbVie, AstraZeneca, Chugai\/Roche, Janssen-Cilag, Gilead, Boehringer\/Ingelheim, Mylan, Galapagos, EUSA-Pharma; Travel grants: Chugai\/Roche, Boehringer\/Ingelheim, Celgene, Medac, UCB, Mylan, Galapagos. Herbert Kellner: Speaker\u2019s bureau: Abbvie, Boehringer, Biogen, Celgene, Celltrion, Fresenius, Galapagos, Hexal, Janssen, Lilly, Medac, MSD, Viatris, Novartis, UCB, Sandoz, Sanofi-Aventis. Ayman Askari: None. Javier De Toro Santos: Consulting fees from Sandoz, AbbVie, Lilly, Janssen-Cilag, Novartis, Galapagos, UCB. Julio Cesar Vazquez Perez-Coleman: Consulting fees from Sandoz, AbbVie, Novartis. Rosario Foti: None. S\u0142awomir Jeka: Consulting fees from Sandoz, UCB, Lilly, Novartis, Abbvie, Roche, Celgene, Gilead, AstraZeneca. Boulos Haraoui: Research grants, Consulting fees: Abbvie, Amgen, Lilly, Pfizer, Sandoz. Yannick Allanore: Consulting fees from Sandoz, Celltrion. Peter Peichl: None. Martin Oehri: None. Masiur Rahman: Employee of Sandoz. Fabricio Furlan: Former employee of Sandoz. New affiliation: STADA. Elisa Romero: Employee of Sandoz. Sohaib Hachaichi: Former employee of Sandoz. New affiliation: Bayer AG. Charlotte Both: Employee of Sandoz. Ines Brueckmann: Employee of Sandoz. Tom Sheeran: Consultant fees from Novartis, Pfizer, Roche, BMS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved for each participating site according to the local regulations. All patients signed an informed consent form that was reviewed and approved by an independent ethics committee or institutional review board. The study design was reviewed by the ethics committees or institutional review boards, and the study was conducted in accordance with the principle of the Declaration of Helsinki. Details of the institutional review boards and ethics committees can be found in Supplementary Table\u00a07.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}